tirzepatide for obesity fda approval Zepbound (tirzepatide) injection, the first and only treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Tirzepatide approved for obesity by

Focus on lean protein at every meal (aim for 60 to 100 grams per day), stay hydrated with at least 64 ounces of water daily, eat smaller meals more frequently, and avoid high-fat, fried, and overly sugary foods that can worsen nausea and GI side effects

A microdosing approach to tirzepatide might start at 10 units (1mg) for the first two weeks before moving to 15 units (1.5mg) and then 20 units (2mg)

Tirzepatide has been also reported to be beneficial in reducing liver fat content

Your address can be updated from the Shipping tab of your account

For life-threatening symptoms or suspected anaphylaxis, call 999

Application and Indication Analysis GLP-1 Weight Loss Drug Market by Indication: Obesity Management Commands 61.4% of Revenue While Cardiovascular and Metabolic Indications Drive Premium Expansion GLP-1 Drug Market Revenue Share, CAGR, and Key Clinical Evidence by Application 2026 Obesity and chronic weight management represents the largest GLP-1 drug market application at 61.4% revenue share in 2026